Skip to main content
Top
Published in: International Urology and Nephrology 8/2023

Open Access 31-05-2023 | Prostatectomy | Urology - Original Paper

Zonal origin of prostate cancer: comparison of long-term outcomes after radical prostatectomy

Authors: Laura Luttrell, Jian Li, Ronald J. Cohen

Published in: International Urology and Nephrology | Issue 8/2023

Login to get access

Abstract

Purpose

To assess the impact of zonal origin on positive bladder neck (BN) margins and prostate-specific antigen (PSA) failure or early adjuvant therapy in the patients with complete long-term follow-up after radical prostatectomy (RP).

Methods

A set of 4512 men were identified who underwent RP in Western Australia (WA) from March 2000 to December 2016 and had complete long-term follow-up. The t-test, Pearson chi-square test and Kaplan–Meier method with the log-rank test were used to evaluate differences between the transition zone (TZ) and peripheral/central zone (PZ/CZ) cancer. Univariate and multivariable Cox proportional hazard regression models were applied to assess parameters on PSA failure and early treatment.

Results

The positive BN margin rate for TZ cancer fell significantly over the study period. However, BN margin rates increased for PZ/CZ cancer over the time. Data of 4512 patients with median follow-up of 9.1 years confirmed that the high-risk TZ tumours with negative margins had a significant lower rate of PSA failure or early treatment compared to those high-risk PZ/CZ tumours with negative margins.

Conclusion

Prostate cancer zonal origin significantly impacts long-term biochemical outcomes in high-risk and margin-negative patients. BN invasion with margin involvement is more frequent in the TZ cancer and can be reduced by pre-operative identification of cancer zonal origin and adjustment of surgical procedures.
Literature
1.
go back to reference McNeal JE, Redwine EA, Freiha FS, Stamey TA (1988) Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12:897–906CrossRefPubMed McNeal JE, Redwine EA, Freiha FS, Stamey TA (1988) Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12:897–906CrossRefPubMed
2.
go back to reference Stamey TA, Sözen TS, Yemoto CM, McNeal JE (1998) Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups. J Urol 159:2009–2012CrossRefPubMed Stamey TA, Sözen TS, Yemoto CM, McNeal JE (1998) Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups. J Urol 159:2009–2012CrossRefPubMed
3.
go back to reference Iremashvili V, Pelaez L, Jordá M, Manoharan M, Rosenberg DL, Soloway MS (2012) Prostate cancers of different zonal origin: clinicopathological characteristics and biochemical outcome after radical prostatectomy. Urology 80:1063–1069CrossRefPubMed Iremashvili V, Pelaez L, Jordá M, Manoharan M, Rosenberg DL, Soloway MS (2012) Prostate cancers of different zonal origin: clinicopathological characteristics and biochemical outcome after radical prostatectomy. Urology 80:1063–1069CrossRefPubMed
4.
go back to reference King CR, Ferrari M, Brooks JD (2009) Prognostic significance of prostate cancer originating from the transition zone. Urol Oncol 27:592–597CrossRefPubMed King CR, Ferrari M, Brooks JD (2009) Prognostic significance of prostate cancer originating from the transition zone. Urol Oncol 27:592–597CrossRefPubMed
5.
go back to reference Teloken PE, Li J, Woods CG, Cohen RJ (2017) The impact of prostate cancer zonal origin on pathological parameters at radical prostatectomy and subsequent biochemical failure. J Urol 198:1316–1323CrossRefPubMed Teloken PE, Li J, Woods CG, Cohen RJ (2017) The impact of prostate cancer zonal origin on pathological parameters at radical prostatectomy and subsequent biochemical failure. J Urol 198:1316–1323CrossRefPubMed
6.
go back to reference Cohen RJ, Shannon BA, Phillips M, Moorin RE, Wheeler TM, Garrett KL (2008) Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features. J Urol 179:1762–1767CrossRefPubMed Cohen RJ, Shannon BA, Phillips M, Moorin RE, Wheeler TM, Garrett KL (2008) Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features. J Urol 179:1762–1767CrossRefPubMed
7.
go back to reference Cohen RJ, McNeal JE, Edgar SG, Robertson T, Dawkins HJS (1998) Characterization of cytoplasmic secretory granules (PSG), in prostatic epithelium and their transformation-induced loss in dysplasia and adenocarcinoma. Hum Pathol 29:1488–1494CrossRefPubMed Cohen RJ, McNeal JE, Edgar SG, Robertson T, Dawkins HJS (1998) Characterization of cytoplasmic secretory granules (PSG), in prostatic epithelium and their transformation-induced loss in dysplasia and adenocarcinoma. Hum Pathol 29:1488–1494CrossRefPubMed
8.
go back to reference Cohen RJ, McNeal JE, Redmond SL et al (2000) Luminal contents of benign and malignant prostatic glands: correspondence to altered secretory mechanism. Hum Pathol 31:94–100CrossRefPubMed Cohen RJ, McNeal JE, Redmond SL et al (2000) Luminal contents of benign and malignant prostatic glands: correspondence to altered secretory mechanism. Hum Pathol 31:94–100CrossRefPubMed
9.
go back to reference Cohen RJ, Beales M, McNeal JE (2000) Prostate secretory granules in normal and neoplastic prostate glands: a diagnostic aid to needle biopsy. Hum Pathol 31:1515–1519CrossRefPubMed Cohen RJ, Beales M, McNeal JE (2000) Prostate secretory granules in normal and neoplastic prostate glands: a diagnostic aid to needle biopsy. Hum Pathol 31:1515–1519CrossRefPubMed
10.
go back to reference Lee S, Walsh S, Woods CG, Bonkhoff H, Cohen RJ (2013) Reliable identification of transition zone prostatic adenocarcinoma in preoperative needle core biopsy. Hum Pathol 44:2331–2337CrossRefPubMed Lee S, Walsh S, Woods CG, Bonkhoff H, Cohen RJ (2013) Reliable identification of transition zone prostatic adenocarcinoma in preoperative needle core biopsy. Hum Pathol 44:2331–2337CrossRefPubMed
11.
go back to reference Cohen RJ, Li J, Shannon T (2016) Prediction of bladder neck invasion and tumor extension to bladder neck margin by prostatic adenocarcinoma: a nomogram using biopsy data including transition zone tumor morphology. Hum Pathol 57:85–90CrossRefPubMed Cohen RJ, Li J, Shannon T (2016) Prediction of bladder neck invasion and tumor extension to bladder neck margin by prostatic adenocarcinoma: a nomogram using biopsy data including transition zone tumor morphology. Hum Pathol 57:85–90CrossRefPubMed
12.
go back to reference O’Neil LM, Walsh S, Cohen RJ, Lee S (2015) Prostate carcinoma with positive margins at radical prostatectomy: role of tumour zonal origin in biochemical recurrence. BJU Int 116:42–48CrossRefPubMed O’Neil LM, Walsh S, Cohen RJ, Lee S (2015) Prostate carcinoma with positive margins at radical prostatectomy: role of tumour zonal origin in biochemical recurrence. BJU Int 116:42–48CrossRefPubMed
13.
go back to reference Lee JJ, Thomas I, Nolley R, Ferrari M, Brooks JD, Leppert JT (2015) Biologic differences between peripheral and transitional zone prostate cancer. Prostate 75:183–190CrossRefPubMed Lee JJ, Thomas I, Nolley R, Ferrari M, Brooks JD, Leppert JT (2015) Biologic differences between peripheral and transitional zone prostate cancer. Prostate 75:183–190CrossRefPubMed
14.
go back to reference Chun FK, Briganti A, Jeldres C et al (2007) Zonal origin of localized prostate cancer does not affect the rate of biochemical recurrence after radical prostatectomy. Eur Urol 51:949–955CrossRefPubMed Chun FK, Briganti A, Jeldres C et al (2007) Zonal origin of localized prostate cancer does not affect the rate of biochemical recurrence after radical prostatectomy. Eur Urol 51:949–955CrossRefPubMed
15.
go back to reference Takamatsu K, Matsumoto K, Shojo K et al (2019) The prognostic value of zonal origin and extraprostatic extension of prostate cancer for biochemical recurrence after radical prostatectomy. Urol Oncol 37:575.e19–25CrossRefPubMed Takamatsu K, Matsumoto K, Shojo K et al (2019) The prognostic value of zonal origin and extraprostatic extension of prostate cancer for biochemical recurrence after radical prostatectomy. Urol Oncol 37:575.e19–25CrossRefPubMed
16.
go back to reference Sato S, Kimura T, Onuma H, Egawa S, Takahashi H (2021) Transition zone prostate cancer is associated with better clinical outcomes than peripheral zone cancer. BJUI Compass 2:169–177CrossRefPubMed Sato S, Kimura T, Onuma H, Egawa S, Takahashi H (2021) Transition zone prostate cancer is associated with better clinical outcomes than peripheral zone cancer. BJUI Compass 2:169–177CrossRefPubMed
17.
go back to reference Augustin H, Hammerer PG, Blonski J et al (2003) Zonal location of prostate cancer: significance for disease-free survival after radical prostatectomy? Urology 62:79–85CrossRefPubMed Augustin H, Hammerer PG, Blonski J et al (2003) Zonal location of prostate cancer: significance for disease-free survival after radical prostatectomy? Urology 62:79–85CrossRefPubMed
Metadata
Title
Zonal origin of prostate cancer: comparison of long-term outcomes after radical prostatectomy
Authors
Laura Luttrell
Jian Li
Ronald J. Cohen
Publication date
31-05-2023
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 8/2023
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-023-03637-7

Other articles of this Issue 8/2023

International Urology and Nephrology 8/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine